早期静脉硫酸镁对动脉瘤性蛛网膜下腔出血脑血管痉挛及迟发性脑缺血的影响:回顾性匹配病例对照分析
德国单中心回顾性匹配病例对照分析,比较确诊后24小时内应用静脉硫酸镁(B组)与未应用(A组)各24例动脉瘤性蛛网膜下腔出血患者;B组脑血管痉挛33% vs A组46%,迟发性脑缺血13% vs 42%,12个月改良Rankin量表评分0-3分良好功能预后B组22例 vs A组15例。
要点
- 确诊后24小时内静脉硫酸镁组脑血管痉挛发生率为33%,低于未用组的46%。
- 硫酸镁组迟发性脑缺血发生率为13%,低于未用组的42%。
- 12个月随访时硫酸镁组良好功能预后(改良Rankin量表评分0-3分)22例,未用组15例。
核心结论
- 本研究中,动脉瘤性蛛网膜下腔出血发病后24小时内接受静脉硫酸镁的患者脑血管痉挛和迟发性脑缺血发生率较低,12个月随访时硫酸镁组更可能获得良好功能预后。
研究设计与样本
- 德国单中心回顾性匹配病例对照分析,按年龄、Fisher分级、吸烟和蛛网膜下腔出血严重程度等已知迟发性脑缺血和脑血管痉挛危险因素进行配对。
- 共196例患者符合纳入标准,风险分层后最终分析纳入48例(年龄54.2±8.1岁;女30例、男18例),分为未用硫酸镁组A组(n=24)和确诊后24小时内应用硫酸镁组B组(n=24)。
主要发现
- 脑血管痉挛B组发生率为33%,A组为46%。
- 迟发性脑缺血B组发生率为13%,A组为42%。
- 12个月时改良Rankin量表评分0-3分的良好功能预后B组22例,A组15例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Magnesium sulfate (MgSO4) is a potential neuroprotective agent for patients with aneurysmal subarachnoid hemorrhage (SAH). We analyzed the effect of early application of intraoperative intravenous MgSO4 and compared cerebral vasospasm (CV), delayed cerebral ischemia (DCI), and neurological outcome in 2 patient cohorts. METHODS: A retrospective matched-pair analysis from patients at a single center in Germany was performed without (group A) and with (group B) MgSO4 application <24 hours after diagnosis. Pairs were matched according to the known risk factors for DCI and CV (age, Fisher grade, smoking, severity of SAH). Incidence of CV and DCI and neurological outcome using the modified Rankin Scale score 3 and 12 months after SAH were recorded. RESULTS: The inclusion criteria were met by 196 patients. After risk stratification, 48 patients were included in the final analysis (age 54.2 ± 8.1 years; 30 women and 18 men) and were assigned to group A (n = 24) or group B (n = 24). CV occurred less frequently in group B (33%) than in group A (46%). Likewise, DCI was present in 13% in group B compared with 42% in group A. After 12 months, 22 patients in group B had a favorable functional outcome (modified Rankin Scale score 0-3) compared with 15 patients in group A. CONCLUSIONS: In this study, the incidence of CV and DCI was lower in patients receiving intravenous MgSO4 within 24 hours after aneurysmal SAH onset. Favorable functional outcome was more likely in the MgSO4 group after 12 months of follow-up.
引用
- Feulner J, Weidinger CS, Dörfler A, et al. Early Intravenous Magnesium Sulfate and Its Impact on Cerebral Vasospasm as well as Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage: A Retrospective Matched Case-Control Analysis. World Neurosurg. 2024. PMID: 38514031. doi:10.1016/j.wneu.2024.03.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。